rescue therapy in refractory acute respiratory distress syndrome but has not been assessed in allogeneic hematopoietic stem cell transplantation recipients. Design: Multicenter, retrospective, observational study. Setting: ICUs in 12 European tertiary care centers (Austria, Germany, France, and Belgium). Patients: All allogeneic hematopoietic stem cell transplantation recipients treated with venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome between 2010 and 2015. Interventions: None. Measurements and Main Results: Thirty-seven patients, nine of whom underwent noninvasive ventilation at the time of extracorporeal membrane oxygenation initiation, were analyzed. ICU admission occurred at a median of 146 (interquartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation. The main reason for acute respiratory distress syndrome was pneumonia in 81% of patients. All but one patient undergoing noninvasive ventilation at extracorporeal membrane oxygenation initiation had to be intubated thereafter. Overall, seven patients (19%) survived to hospital discharge and were alive and in remission of their hematologic disease after a follow-up of 18 (range, months. Only one of 24 patients (4%) initiated on extracorporeal membrane oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survived compared to six of 13 (46%) of those treated thereafter (p < 0.01). Fourteen patients (38%) experienced bleeding events, of which six (16%) were associated with fatal outcomes. Conclusions: Discouraging survival rates in patients treated early after allogeneic hematopoietic stem cell transplantation do not support the use of extracorporeal membrane oxygenation for acute respiratory distress syndrome in this group. On the contrary, longterm allogeneic hematopoietic stem cell transplantation recipients otherwise eligible for full-code ICU management may be potential candidates for extracorporeal membrane oxygenation therapy in case of severe acute respiratory distress syndrome failing conventional measures. (Crit Care Med 2017; 45:e500-e507) Key Words: acute respiratory distress syndrome; extracorporeal membrane oxygenation; respiratory insufficiency; stem cell transplantation A llogeneic hematopoietic stem cell transplantation (ASCT) is increasingly performed to treat various malignant and nonmalignant hematologic diseases. Reports from the United States (1) and Europe (2) mention the respective record numbers of 8,000 and 16,000 ASCTs carried out in 2014. The occurrence rate of the acute respiratory distress syndrome (ARDS) was recently reported to be as high as 16% within the first year following ASCT, and three out of four of these patients present with severe ARDS (3, 4) . In the light of these numbers, ASCT recipients with severe ARDS may be a quantitatively relevant target population to consider for treatment with extracorporeal membrane oxygenation (ECMO). Hence, specific recognition of these patients by critical care professionals seems mandatory.
The use of ECMO in ASCT recipients has so far only been reported as single case or in small series (5) (6) (7) (8) (9) (10) . Results from these reports together with the unfavorable outcome seen in conventional mechanical ventilation have driven discussions about the futility of ECMO in the setting of ASCT (11, 12) . However, given the limited available data, there is a paucity of evidence to guide strict reasoning. With this study, we set out to report the characteristics and outcome of ASCT recipients treated with ECMO for ARDS in 12 European centers. The provided data are intended to strengthen clinical decision making about the use of ECMO under certain circumstances or in specific subgroups of patients following ASCT.
MATERIALS AND METHODS
We retrospectively studied the clinical courses of all adult ASCT recipients (18 yr old or older) treated with venovenous ECMO for ARDS in the ICUs of 12 European tertiary care centers (one respectively from Austria, Belgium, and Norway, three from France, and six from Germany) between 2010 and 2015. The study was approved by the ethics committee of the Medical University of Vienna and conducted in accordance with Good Clinical Practice guidelines and the amended Declaration of Helsinki. The term "ECMO" refers to venovenous ECMO throughout the article. Two of the patients were part of an already published case series (5) .
Baseline data were recorded for the time immediately before initiation of ECMO therapy. ARDS was defined and graded according to the Berlin definition (4) .The presence of circulatory, renal, or liver dysfunction at baseline was defined as a Sequential Organ Failure Assessment score (13) greater than or equal to 2 in the respective domain. The Simplified Acute Physiology Score II (SAPS II) (14, 15) at ICU admission was used to assess the severity of acute illness, the Charlson Comorbidity Index (CCI) (16) at admission to account for comorbidities, and the Lung Injury Score (17) to determine the extent of lung damage in invasively ventilated patients at baseline. Driving pressure (ΔP) in patients undergoing invasive mechanical ventilation (IMV) was calculated as described elsewhere (18) .
Bleeding was defined as requirement of two or more units of packed RBCs due to an obvious bleeding event, and noted as major if a surgical or interventional procedure was required, as well as in cases of intracerebral hemorrhage or fatal outcome. Neutropenia was defined as an absolute neutrophil count less than 500 per microliter. In patients with more than one episode of ECMO, baseline variables associated with the first ECMO episode were analyzed, whereas all episodes were included in the calculation of the total duration of ECMO therapy.
Continuous data are presented as median and interquartile range (25-75%), dichotomous data as number and percentage. Receiver operating characteristic analysis was used to identify the time from ASCT to initiation of ECMO to best discriminate between survivors and nonsurvivors and was then rounded to the nearest tenth not changing the properties of the discriminator. Data were compared between survivors and nonsurvivors using Fisher exact test for dichotomous variables and the Mann-Whitney U test for continuous variables.
Differences were considered statistically significant when p value was less than 0.05. Statistical tests were performed using the SPSS 22 software package (IBM, Armonk, NY).
RESULTS
Thirty-seven ASCT recipients with ARDS treated with a total of 39 ECMO episodes were included. The male-to-female ratio was 1.2:1, age 37 (26-49) years, CCI 0 (0-1), and SAPS II 56 (42-67). ICU admission occurred 139 (20-301) days after stem cell transplantation. Sixteen patients (43%) were admitted to the ICU and had not been temporarily discharged after ASCT. Individual patient characteristics are depicted in the Supplementary Table 1 (Supplemental Digital Content 1, http://links. lww.com/CCM/C383).
Characteristics of the Hematopoietic Stem Cell Transplantation
ASCT-related characteristics are described in Table 1 . Hematologic malignancy was the underlying disease in 34 patients Other malignant condition 4 (11) 2 (7) 2 (29) Nonmalignant disease 3 (8) 2 (7) 1 (14) Conditioning Table 2) .
ECMO Therapy and Complications
ECMO was initiated 146 (27-321) days following ASCT, 4 (1-7) days after ICU admission, and 2 (0-6) days after intubation. All but one patient undergoing NIV at baseline were intubated 5 (2-9) days after start of ECMO. Lowest leukocyte counts observed were 0.9 (0.2-2.7) G/L with periods of neutropenia recorded in 18 patients (49%), and lowest platelet counts 8 (5-17) G/L with episodes of thrombocytopenia less than 50 G/L in 92% (n = 34) of patients. During ECMO, 78% (n = 29) and 51% (n = 19) of patients required vasopressors and renal replacement therapy, respectively. Bleeding events were documented in 14 patients (38%); six (16%) of these were regarded major. Latter comprised intracranial hemorrhage leading to discontinuation of active therapy and fatal multiple organ failure involving uncontrolled bleeding in three patients each (patients 4, 8 were withheld from anticoagulation due to thrombocytopenia (median platelet count at initiation, 17 G/L; range, 2-50 G/L), the remainder received heparin. Bleeding events occurred in four of 14 when compared with 10 of 23 in the heparin group (p = 0.49), one clotting event was noted in the former. We did not find significant differences of the platelet counts at ECMO baseline or during the course of ECMO treatment between patients with and without bleeding events (data not shown). Ischemic stroke was noted in three patients during ECMO with one progressing to intracerebral hemorrhage (included into the above stated patients). Thus, in all, five patients (14%) experienced major cerebral complications during ECMO. No events of accidental decannulation were reported.
Outcome and Survival Comparison
Survival of the last ECMO episode was 9/37 (24%). Two patients successfully weaned from ECMO died in the ICU. The ICU and hospital survival rate was 7/37 (19%), and all survivors were alive and in remission of their disease 18 (range, 5-30) months after ICU discharge.
ECMO was initiated after a median time of more than 1 year following ASCT in hospital survivors (485 [270-976] vs 100 
DISCUSSION
In this study, we analyzed the characteristics and outcomes of 37 ASCT recipients treated with ECMO for ARDS in 12 European centers. The ICU survival rate was 19%, which is markedly lower than those reported in non-ASCT patients with ARDS undergoing ECMO (19, 20) . Notably, there was a distinct and significant difference in the survival rates of patients treated early or late after ASCT (4% vs 46%). All survivors were discharged from the hospital, alive and in remission after long-term follow-up.
Several studies on heterogeneous ASCT populations undergoing IMV due to acute respiratory failure of all degrees have currently reported on survival rates of approximately 30% (3, 21, 22) . However, in the so far largest study on outcomes of more than 1,000 mainly hematologic patients with ARDS, the estimated 90-day mortality of those with "severe" ARDS exceeded 80%, and ASCT status was an independent risk factor for even higher mortality (23) . Despite these data, we found it difficult to match our findings with proper comparison groups, as ASCT patients with severe ARDS have so far not been characterized in detail. This is somewhat surprising, since according to a recent investigation, every sixth patient within 1 year after ASCT develops ARDS (3) . ECMO in our study was initiated as a rescue therapy in patients with severe ARDS combined with multiple organ dysfunction, previously reported fatal (21, (24) (25) (26) (27) . Nevertheless, with respect to important prognostic variables, our cohort did not seem to differ from the mentioned non-ECMO ASCT cohorts, as we found rather low rates of nonremission status, acute GvHD, and invasive mold infections (3, 21, 22) . This reflects adherence to expert recommendations on ICU admission criteria for patients after ASCT in our group (28) and, furthermore, suggests that our cohort may compare as a subgroup representative of ASCT recipients currently admitted to ICUs of dedicated centers (21).
As the major finding, our data indicate that a significant proportion of long-term ASCT recipients with refractory severe ARDS may be candidates for ECMO therapy, whereas prognosis of patients early after ASCT is very grim. Several aspects may explain this finding. First, immunocompromised state, a well-known risk factor in large ECMO cohorts (29, 30) , gradually improves over time following ASCT and is accompanied by tapering of immunosuppressive medication (31) . Second, acute GvHD predisposes to multiple organ dysfunction associated with detrimental outcome in critical illness (21, 24, 25) . In line with this, none of the patients with acute GvHD in our cohort survived. Third, idiopathic noninfectious pulmonary complications after ASCT, such as diffuse alveolar hemorrhage or idiopathic pneumonia syndrome, have been associated with excess mortality rates (32, 33) , and may have been underreported in our cohort given the number of patients with microbiologically negative pneumonia around engraftment.
In contrast, the question can be raised when or whether previous ASCT may be regarded a less important detail rather than a major contributor to morbidity and mortality. Indeed, four survivors were admitted more than 1 year after ASCT, and two of these neither displayed signs of chronic GvHD nor received immunosuppressive therapies. The majority of long-term ASCT survivors presented with pulmonary infections and identified pathogens, both factors associated with favorable outcome in hematologic patients with respiratory failure (23, 34) . Available data on ASCT patients do not give compelling evidence that the underlying malignancy itself (in contrast to the remission status) correlates with survival in case of critical illness (3, 21, 25) . Therefore, the difference in our series between survivors and nonsurvivors with respect to the underlying disease must be interpreted with extreme caution and in the light of small patient numbers.
Importantly, all but three patients developed pronounced thrombocytopenia during ECMO. Bleeding occurred frequently and was deemed major in 16%, including three fatal cases of intracranial hemorrhage. Considering ischemic stroke in two additional patients raises the rate of critical cerebral complications to 14%. Albeit bleeding remains a major issue, we recommend to withhold anticoagulation in patients with deep thrombocytopenia on heparinized circuits, as performed in several of our patients and recently presented in small series (5, 35) .
Surprisingly, only half of the IMV patients received neuromuscular blockers and only a third underwent prone positioning. Hence, evidence-based adjunctive measures had not been fully exploited in all patients, which prompts speculation whether their use could have obviated ECMO in some cases. Although this is definitely a limitation to the interpretation of our findings, the apparent underuse of these measures in clinical practice likely also affects findings from other observational and even interventional ECMO trials (36, 37) . As a contributing factor in our series, the respective landmark trials were just published during the study period (38, 39) , and complete translation of their findings could, thus, not be expected.
In consequence to the low success rate and the high burden of complications, we feel that ECMO should be discouraged for ARDS during the peri-or early posttransplant period. In the remaining ASCT patients, we suggest to strictly reserve its use to cases of severe ARDS failing protective ventilation (40) together with supportive therapeutic measures, such as prone positioning (38) and neuromuscular blocking agents (39) . In addition, we recommend 1) to very carefully select patients with preferably no additional organ dysfunctions and no signs of refractory acute GvHD, 2) to early inform patients and families about the limited prognosis, and 3) to discuss and respect their preferences with regards to end-of-life issues as a cornerstone of the decision process. Conservative considerations also apply to the use of ECMO in patients with NIV failure for preventing endotracheal intubation. Based on encouraging findings from a small and uncontrolled cohort study (41) , nine of our patients were placed on ECMO while undergoing failing NIV. However, all but one had to be intubated eventually. Thus, our preliminary data do not suggest feasibility of the "awake ECMO" concept in ASCT patients.
The formal limitations of our report are the ones typically associated with retrospective analyses and cover data completeness, quality, and interpretation. Most importantly, we can neither exclude unmeasured confounders nor present a control group or uniform ECMO inclusion criteria. However, all of our patients undergoing IMV would have fulfilled the strict inclusion criteria of the so far only positive interventional ECMO trial with respect to clinical outcome (37) , and thus, may be considered ECMO candidates to the best available evidence. Furthermore, we did not provide extended data on or a uniform strategy for ECMO and ventilator settings, which, unfortunately, is a common limitation of most observational and interventional ECMO trials. Likewise, questions regarding risks other than bleeding, measures to avoid complications, and the role of an "awake ECMO" concept cannot be answered by our study. Even though we report the by far largest number of ASCT patients on ECMO, numbers are rather small, dictating cautious interpretation of statistical findings. Furthermore, the observational design does not allow for proofing causal relations between ECMO and outcome. Next steps to overcome the persisting lack of evidence in the management of ASCT patients with severe ARDS warrant better characterizations of outcome and prognostic factors, which may serve as a basis for well designed case-control studies or interventional protocols including ECMO in selected subgroups of patients.
CONCLUSIONS
Discouraging survival rates in patients treated early after ASCT do not support the use of ECMO for ARDS in this group. On the contrary, long-term ASCT recipients otherwise eligible for full-code ICU management may be potential candidates for ECMO therapy in case of severe ARDS failing conventional measures.
